Privately held Vascular Control develops devices to control bleeding during obstetric and gynecologic procedures. Ethicon makes instruments for general surgery, wound management, women's health and cardiovascular surgery.
"This represents a strong, strategic fit with our gynecologic business," said Sheri McCoy, a J&J executive responsible for the Ethicon business. "The technology and knowledge we'll gain will enable us to expand our ability to create new therapies for women," she said.
Specific financial terms of the transaction weren't disclosed.J&J's shares dipped 18 cents to $58.53 Tuesday.